News & Research

Find all the latest research, news and updates on Alzheimer’s disease blood-based biomarkers. Stay up to date with the latest educational materials from the BBM Workgroup.

Featured Stories

Featured

FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease

The Global CEO Initiative on Alzheimer’s Disease Launches Groundbreaking Alzheimer’s Blood Test Performance Database for Clinicians

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med

BBM Workgroup Activities & Educational Content:

News and Research

Mar 27, 2025

The Global CEO Initiative on Alzheimer’s Disease Launches Groundbreaking Alzheimer’s Blood Test Performance Database for Clinicians

Mar 27, 2025

Jan 14, 2025

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med

Jan 14, 2025

Oct 25, 2024

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Oct 25, 2024

Aug 6, 2024

Plain Language Summary of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease”

Aug 6, 2024

Jul 30, 2024

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Jul 30, 2024

Jun 12, 2024

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Jun 12, 2024

May 10, 2024

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

May 10, 2024

Mar 20, 2024

The Global CEO Initiative on Alzheimer’s Disease Announces Expansion of its Blood-Based Biomarker Workgroup in 2024

Mar 20, 2024

Mar 19, 2024

CEOi Blood-Based Biomarker Symposium at AAGP 2024

Mar 19, 2024

Filter by Category: Research articles | News | Press Releases | Workgroup Activities | Education

Emily Scholler 3/27/25 Emily Scholler 3/27/25

The Global CEO Initiative on Alzheimer’s Disease Launches Groundbreaking Alzheimer’s Blood Test Performance Database for Clinicians

Emily Scholler 1/14/25 Emily Scholler 1/14/25

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med

Emily Scholler 10/25/24 Emily Scholler 10/25/24

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Emily Scholler 8/6/24 Emily Scholler 8/6/24

Plain Language Summary of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease”

Emily Scholler 7/30/24 Emily Scholler 7/30/24

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Emily Scholler 6/12/24 Emily Scholler 6/12/24

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Emily Scholler 5/10/24 Emily Scholler 5/10/24

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

Emily Scholler 3/20/24 Emily Scholler 3/20/24

The Global CEO Initiative on Alzheimer’s Disease Announces Expansion of its Blood-Based Biomarker Workgroup in 2024

The Global CEO Initiative on Alzheimer’s Disease (CEOi) is excited to announce the second phase of its Blood-based Biomarker (BBM) Workgroup in 2024.

Knapsack 3/19/24 Knapsack 3/19/24

CEOi Blood-Based Biomarker Symposium at AAGP 2024

CEOi held a blood-based biomarker symposium at the American Association for Geriatric Psychiatry (AAGP) 2024 Annual Meeting, “Unleashing Diagnostic Innovation: Clinical Implementation of Blood-Based Biomarkers for Alzheimer’s Disease.”

News & Research

Featured Stories

BBM Workgroup Activities & Educational Content:

The Global CEO Initiative on Alzheimer’s Disease Launches Groundbreaking Alzheimer’s Blood Test Performance Database for Clinicians

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Plain Language Summary of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease”

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

The Global CEO Initiative on Alzheimer’s Disease Announces Expansion of its Blood-Based Biomarker Workgroup in 2024

CEOi Blood-Based Biomarker Symposium at AAGP 2024

Navigation

Follow Us